SCHEMBL7000166

SCHEMBL7000166

CCOC(=O)C(C)Oc1ccc2c(c1[N+](=O)[O-])CCC2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
HPGD P15428 6/20 0.42
KDM4E B2RXH2 5/20 0.42
MAPT P10636 3/20 0.42
TSHR P16473 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
HSD17B10 Q99714 3/20 0.42
MAPK1 P28482 2/20 0.42
ALOX15 P16050 1/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NR5A1 Q13285 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.34
NLRP3 Q96P20 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6994414 0.98 ALDH1A1 (0.44) ALDH1A1HPGDKDM4EMAPTTSHR
SCHEMBL7704925 0.87 MEN1 (0.40) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL6998270 0.85 MEN1 (0.43) ALDH1A1HPGDKDM4EMAPTTSHR
SCHEMBL6999622 0.85 ALDH1A1 (0.38) ALDH1A1HPGDKDM4EMAPTTSHR
SCHEMBL6993231 0.85 ALDH1A1 (0.38) ALDH1A1HPGDKDM4EMAPTTSHR
SCHEMBL7713466 0.85 MEN1 (0.40) ALDH1A1HPGDKDM4EMAPTTSHR
SCHEMBL8113280 0.84 MEN1 (0.37) ALDH1A1HPGDKDM4EMAPTTSHR
SCHEMBL9163910 0.79 MAPT (0.40) ALDH1A1HPGDKDM4EMAPTNPSR1
SCHEMBL9165831 0.79 PDK1 (0.37) ALDH1A1KDM4EMAPTMAPK1MEN1
SCHEMBL7710377 0.78 ALDH1A1 (0.47) ALDH1A1HPGDKDM4EMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed